nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—FGFR2—uterine cancer	0.482	1	CbGaD
Thalidomide—CYP1A1—Progesterone—uterine cancer	0.0463	0.188	CbGbCtD
Thalidomide—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0282	0.114	CbGbCtD
Thalidomide—CYP3A5—Progesterone—uterine cancer	0.0278	0.113	CbGbCtD
Thalidomide—PTGS2—Etoposide—uterine cancer	0.0246	0.0994	CbGbCtD
Thalidomide—CYP2C19—Progesterone—uterine cancer	0.0224	0.0908	CbGbCtD
Thalidomide—PTGS1—Etoposide—uterine cancer	0.0207	0.0839	CbGbCtD
Thalidomide—CYP1A2—Progesterone—uterine cancer	0.0207	0.0838	CbGbCtD
Thalidomide—CYP2C9—Progesterone—uterine cancer	0.0187	0.0755	CbGbCtD
Thalidomide—CYP2E1—Etoposide—uterine cancer	0.016	0.0648	CbGbCtD
Thalidomide—CYP3A5—Etoposide—uterine cancer	0.0124	0.0504	CbGbCtD
Thalidomide—CYP1A2—Etoposide—uterine cancer	0.00926	0.0375	CbGbCtD
Thalidomide—FGFR2—exocrine gland—uterine cancer	0.00238	0.0484	CbGeAlD
Thalidomide—NFKB1—myometrium—uterine cancer	0.00176	0.0357	CbGeAlD
Thalidomide—TNF—vagina—uterine cancer	0.00163	0.033	CbGeAlD
Thalidomide—CRBN—myometrium—uterine cancer	0.00147	0.03	CbGeAlD
Thalidomide—NFKB1—uterine cervix—uterine cancer	0.00137	0.0278	CbGeAlD
Thalidomide—PTGS1—oviduct—uterine cancer	0.00131	0.0267	CbGeAlD
Thalidomide—NFKB1—decidua—uterine cancer	0.0013	0.0265	CbGeAlD
Thalidomide—NFKB1—renal system—uterine cancer	0.00128	0.026	CbGeAlD
Thalidomide—NFKB1—endometrium—uterine cancer	0.00124	0.0251	CbGeAlD
Thalidomide—NFKB1—mammalian vulva—uterine cancer	0.0012	0.0243	CbGeAlD
Thalidomide—CRBN—uterine cervix—uterine cancer	0.00115	0.0233	CbGeAlD
Thalidomide—NFKB1—uterus—uterine cancer	0.00114	0.0232	CbGeAlD
Thalidomide—CRBN—decidua—uterine cancer	0.00109	0.0222	CbGeAlD
Thalidomide—CRBN—renal system—uterine cancer	0.00107	0.0218	CbGeAlD
Thalidomide—TNF—lymph node—uterine cancer	0.00105	0.0214	CbGeAlD
Thalidomide—CRBN—endometrium—uterine cancer	0.00104	0.0211	CbGeAlD
Thalidomide—FGFR2—epithelium—uterine cancer	0.00104	0.0211	CbGeAlD
Thalidomide—FGFR2—uterine cervix—uterine cancer	0.00103	0.0209	CbGeAlD
Thalidomide—NFKB1—female reproductive system—uterine cancer	0.00102	0.0208	CbGeAlD
Thalidomide—CRBN—mammalian vulva—uterine cancer	0.001	0.0204	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—uterine cancer	0.000998	0.0203	CbGeAlD
Thalidomide—Menadione—MTHFR—uterine cancer	0.000979	1	CrCbGaD
Thalidomide—FGFR2—renal system—uterine cancer	0.000961	0.0195	CbGeAlD
Thalidomide—CRBN—uterus—uterine cancer	0.000955	0.0194	CbGeAlD
Thalidomide—NFKB1—female gonad—uterine cancer	0.000932	0.019	CbGeAlD
Thalidomide—NFKB1—vagina—uterine cancer	0.000927	0.0188	CbGeAlD
Thalidomide—PTGS1—artery—uterine cancer	0.000868	0.0177	CbGeAlD
Thalidomide—CRBN—female reproductive system—uterine cancer	0.000859	0.0175	CbGeAlD
Thalidomide—FGFR2—uterus—uterine cancer	0.000856	0.0174	CbGeAlD
Thalidomide—PTGS2—artery—uterine cancer	0.00083	0.0169	CbGeAlD
Thalidomide—CRBN—female gonad—uterine cancer	0.000781	0.0159	CbGeAlD
Thalidomide—CRBN—vagina—uterine cancer	0.000777	0.0158	CbGeAlD
Thalidomide—FGFR2—female reproductive system—uterine cancer	0.000769	0.0156	CbGeAlD
Thalidomide—FGFR2—female gonad—uterine cancer	0.0007	0.0142	CbGeAlD
Thalidomide—NFKB1—lymph node—uterine cancer	0.000599	0.0122	CbGeAlD
Thalidomide—CRBN—lymph node—uterine cancer	0.000502	0.0102	CbGeAlD
Thalidomide—PTGS2—myometrium—uterine cancer	0.000401	0.00816	CbGeAlD
Thalidomide—CYP1A1—epithelium—uterine cancer	0.000375	0.00762	CbGeAlD
Thalidomide—CYP1A1—uterine cervix—uterine cancer	0.000372	0.00756	CbGeAlD
Thalidomide—CYP3A5—uterine cervix—uterine cancer	0.000363	0.00739	CbGeAlD
Thalidomide—CYP1A2—renal system—uterine cancer	0.000352	0.00717	CbGeAlD
Thalidomide—CYP1A1—renal system—uterine cancer	0.000348	0.00707	CbGeAlD
Thalidomide—CYP3A5—renal system—uterine cancer	0.00034	0.00691	CbGeAlD
Thalidomide—PTGS1—epithelium—uterine cancer	0.000329	0.0067	CbGeAlD
Thalidomide—PTGS1—uterine cervix—uterine cancer	0.000326	0.00664	CbGeAlD
Thalidomide—CYP1A1—mammalian vulva—uterine cancer	0.000325	0.00661	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—uterine cancer	0.000317	0.00645	CbGeAlD
Thalidomide—CYP2E1—renal system—uterine cancer	0.000317	0.00645	CbGeAlD
Thalidomide—PTGS2—epithelium—uterine cancer	0.000315	0.0064	CbGeAlD
Thalidomide—CYP2C19—vagina—uterine cancer	0.000313	0.00636	CbGeAlD
Thalidomide—PTGS2—uterine cervix—uterine cancer	0.000312	0.00635	CbGeAlD
Thalidomide—CYP1A1—uterus—uterine cancer	0.00031	0.0063	CbGeAlD
Thalidomide—PTGS1—renal system—uterine cancer	0.000305	0.00621	CbGeAlD
Thalidomide—PTGS2—smooth muscle tissue—uterine cancer	0.000303	0.00617	CbGeAlD
Thalidomide—PTGS1—endometrium—uterine cancer	0.000295	0.00601	CbGeAlD
Thalidomide—PTGS2—renal system—uterine cancer	0.000292	0.00594	CbGeAlD
Thalidomide—PTGS1—mammalian vulva—uterine cancer	0.000286	0.00581	CbGeAlD
Thalidomide—PTGS2—endometrium—uterine cancer	0.000282	0.00574	CbGeAlD
Thalidomide—CYP1A1—female reproductive system—uterine cancer	0.000278	0.00566	CbGeAlD
Thalidomide—PTGS1—uterus—uterine cancer	0.000272	0.00553	CbGeAlD
Thalidomide—CYP2C9—female reproductive system—uterine cancer	0.000268	0.00545	CbGeAlD
Thalidomide—PTGS2—uterus—uterine cancer	0.00026	0.00529	CbGeAlD
Thalidomide—CYP2E1—female reproductive system—uterine cancer	0.000254	0.00516	CbGeAlD
Thalidomide—CYP1A1—female gonad—uterine cancer	0.000253	0.00515	CbGeAlD
Thalidomide—CYP1A1—vagina—uterine cancer	0.000252	0.00512	CbGeAlD
Thalidomide—CYP3A5—female gonad—uterine cancer	0.000248	0.00504	CbGeAlD
Thalidomide—CYP3A5—vagina—uterine cancer	0.000246	0.00501	CbGeAlD
Thalidomide—PTGS1—female reproductive system—uterine cancer	0.000245	0.00497	CbGeAlD
Thalidomide—PTGS2—female reproductive system—uterine cancer	0.000234	0.00475	CbGeAlD
Thalidomide—PTGS1—female gonad—uterine cancer	0.000223	0.00453	CbGeAlD
Thalidomide—PTGS1—vagina—uterine cancer	0.000221	0.0045	CbGeAlD
Thalidomide—PTGS2—female gonad—uterine cancer	0.000213	0.00433	CbGeAlD
Thalidomide—PTGS2—vagina—uterine cancer	0.000211	0.0043	CbGeAlD
Thalidomide—CYP1A1—lymph node—uterine cancer	0.000163	0.00331	CbGeAlD
Thalidomide—PTGS1—lymph node—uterine cancer	0.000143	0.00291	CbGeAlD
Thalidomide—PTGS2—lymph node—uterine cancer	0.000137	0.00278	CbGeAlD
Thalidomide—Bronchitis—Epirubicin—uterine cancer	5.32e-05	0.000375	CcSEcCtD
Thalidomide—Diarrhoea—Dactinomycin—uterine cancer	5.31e-05	0.000374	CcSEcCtD
Thalidomide—Pancytopenia—Epirubicin—uterine cancer	5.26e-05	0.000371	CcSEcCtD
Thalidomide—Hypotension—Etoposide—uterine cancer	5.25e-05	0.00037	CcSEcCtD
Thalidomide—Muscular weakness—Doxorubicin—uterine cancer	5.23e-05	0.000368	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Doxorubicin—uterine cancer	5.23e-05	0.000368	CcSEcCtD
Thalidomide—Neutropenia—Epirubicin—uterine cancer	5.18e-05	0.000365	CcSEcCtD
Thalidomide—Abdominal distension—Doxorubicin—uterine cancer	5.16e-05	0.000363	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Epirubicin—uterine cancer	5.15e-05	0.000363	CcSEcCtD
Thalidomide—Influenza—Doxorubicin—uterine cancer	5.12e-05	0.000361	CcSEcCtD
Thalidomide—Dysphagia—Doxorubicin—uterine cancer	5.12e-05	0.000361	CcSEcCtD
Thalidomide—Pollakiuria—Epirubicin—uterine cancer	5.11e-05	0.00036	CcSEcCtD
Thalidomide—Eosinophilia—Doxorubicin—uterine cancer	5.07e-05	0.000357	CcSEcCtD
Thalidomide—Photosensitivity reaction—Epirubicin—uterine cancer	5.05e-05	0.000356	CcSEcCtD
Thalidomide—Paraesthesia—Etoposide—uterine cancer	5.04e-05	0.000355	CcSEcCtD
Thalidomide—Weight increased—Epirubicin—uterine cancer	5.04e-05	0.000355	CcSEcCtD
Thalidomide—Pancreatitis—Doxorubicin—uterine cancer	5.02e-05	0.000354	CcSEcCtD
Thalidomide—Weight decreased—Epirubicin—uterine cancer	5.01e-05	0.000353	CcSEcCtD
Thalidomide—Dyspnoea—Etoposide—uterine cancer	5.01e-05	0.000353	CcSEcCtD
Thalidomide—Hyperglycaemia—Epirubicin—uterine cancer	4.99e-05	0.000352	CcSEcCtD
Thalidomide—Somnolence—Etoposide—uterine cancer	4.99e-05	0.000352	CcSEcCtD
Thalidomide—Angina pectoris—Doxorubicin—uterine cancer	4.99e-05	0.000352	CcSEcCtD
Thalidomide—Pneumonia—Epirubicin—uterine cancer	4.97e-05	0.00035	CcSEcCtD
Thalidomide—Infestation—Epirubicin—uterine cancer	4.94e-05	0.000348	CcSEcCtD
Thalidomide—Infestation NOS—Epirubicin—uterine cancer	4.94e-05	0.000348	CcSEcCtD
Thalidomide—Drowsiness—Epirubicin—uterine cancer	4.94e-05	0.000348	CcSEcCtD
Thalidomide—Vomiting—Dactinomycin—uterine cancer	4.93e-05	0.000348	CcSEcCtD
Thalidomide—Bronchitis—Doxorubicin—uterine cancer	4.93e-05	0.000347	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Epirubicin—uterine cancer	4.89e-05	0.000345	CcSEcCtD
Thalidomide—Rash—Dactinomycin—uterine cancer	4.89e-05	0.000345	CcSEcCtD
Thalidomide—Decreased appetite—Etoposide—uterine cancer	4.88e-05	0.000344	CcSEcCtD
Thalidomide—Pancytopenia—Doxorubicin—uterine cancer	4.87e-05	0.000343	CcSEcCtD
Thalidomide—Renal failure—Epirubicin—uterine cancer	4.85e-05	0.000342	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Etoposide—uterine cancer	4.85e-05	0.000342	CcSEcCtD
Thalidomide—Fatigue—Etoposide—uterine cancer	4.84e-05	0.000341	CcSEcCtD
Thalidomide—Neuropathy peripheral—Epirubicin—uterine cancer	4.84e-05	0.000341	CcSEcCtD
Thalidomide—Stomatitis—Epirubicin—uterine cancer	4.81e-05	0.000339	CcSEcCtD
Thalidomide—Pain—Etoposide—uterine cancer	4.8e-05	0.000338	CcSEcCtD
Thalidomide—Constipation—Etoposide—uterine cancer	4.8e-05	0.000338	CcSEcCtD
Thalidomide—Conjunctivitis—Epirubicin—uterine cancer	4.8e-05	0.000338	CcSEcCtD
Thalidomide—Neutropenia—Doxorubicin—uterine cancer	4.79e-05	0.000338	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Doxorubicin—uterine cancer	4.76e-05	0.000336	CcSEcCtD
Thalidomide—Sweating—Epirubicin—uterine cancer	4.73e-05	0.000334	CcSEcCtD
Thalidomide—Pollakiuria—Doxorubicin—uterine cancer	4.73e-05	0.000334	CcSEcCtD
Thalidomide—Haematuria—Epirubicin—uterine cancer	4.71e-05	0.000332	CcSEcCtD
Thalidomide—Photosensitivity reaction—Doxorubicin—uterine cancer	4.68e-05	0.00033	CcSEcCtD
Thalidomide—Weight increased—Doxorubicin—uterine cancer	4.66e-05	0.000329	CcSEcCtD
Thalidomide—Epistaxis—Epirubicin—uterine cancer	4.66e-05	0.000328	CcSEcCtD
Thalidomide—Weight decreased—Doxorubicin—uterine cancer	4.63e-05	0.000327	CcSEcCtD
Thalidomide—Sinusitis—Epirubicin—uterine cancer	4.63e-05	0.000326	CcSEcCtD
Thalidomide—Feeling abnormal—Etoposide—uterine cancer	4.63e-05	0.000326	CcSEcCtD
Thalidomide—Hyperglycaemia—Doxorubicin—uterine cancer	4.62e-05	0.000326	CcSEcCtD
Thalidomide—Nausea—Dactinomycin—uterine cancer	4.61e-05	0.000325	CcSEcCtD
Thalidomide—Agranulocytosis—Epirubicin—uterine cancer	4.61e-05	0.000325	CcSEcCtD
Thalidomide—Pneumonia—Doxorubicin—uterine cancer	4.59e-05	0.000324	CcSEcCtD
Thalidomide—Gastrointestinal pain—Etoposide—uterine cancer	4.59e-05	0.000324	CcSEcCtD
Thalidomide—Infestation NOS—Doxorubicin—uterine cancer	4.57e-05	0.000322	CcSEcCtD
Thalidomide—Infestation—Doxorubicin—uterine cancer	4.57e-05	0.000322	CcSEcCtD
Thalidomide—Drowsiness—Doxorubicin—uterine cancer	4.57e-05	0.000322	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	4.53e-05	0.000319	CcSEcCtD
Thalidomide—Bradycardia—Epirubicin—uterine cancer	4.51e-05	0.000318	CcSEcCtD
Thalidomide—Renal failure—Doxorubicin—uterine cancer	4.49e-05	0.000316	CcSEcCtD
Thalidomide—Neuropathy peripheral—Doxorubicin—uterine cancer	4.48e-05	0.000316	CcSEcCtD
Thalidomide—Urticaria—Etoposide—uterine cancer	4.46e-05	0.000314	CcSEcCtD
Thalidomide—Stomatitis—Doxorubicin—uterine cancer	4.45e-05	0.000314	CcSEcCtD
Thalidomide—Rhinitis—Epirubicin—uterine cancer	4.44e-05	0.000313	CcSEcCtD
Thalidomide—Abdominal pain—Etoposide—uterine cancer	4.44e-05	0.000313	CcSEcCtD
Thalidomide—Body temperature increased—Etoposide—uterine cancer	4.44e-05	0.000313	CcSEcCtD
Thalidomide—Conjunctivitis—Doxorubicin—uterine cancer	4.44e-05	0.000313	CcSEcCtD
Thalidomide—Hepatitis—Epirubicin—uterine cancer	4.43e-05	0.000312	CcSEcCtD
Thalidomide—Hypoaesthesia—Epirubicin—uterine cancer	4.41e-05	0.000311	CcSEcCtD
Thalidomide—Pharyngitis—Epirubicin—uterine cancer	4.4e-05	0.00031	CcSEcCtD
Thalidomide—Sweating—Doxorubicin—uterine cancer	4.38e-05	0.000309	CcSEcCtD
Thalidomide—Urinary tract disorder—Epirubicin—uterine cancer	4.38e-05	0.000308	CcSEcCtD
Thalidomide—Oedema peripheral—Epirubicin—uterine cancer	4.37e-05	0.000308	CcSEcCtD
Thalidomide—Haematuria—Doxorubicin—uterine cancer	4.36e-05	0.000307	CcSEcCtD
Thalidomide—Urethral disorder—Epirubicin—uterine cancer	4.34e-05	0.000306	CcSEcCtD
Thalidomide—Epistaxis—Doxorubicin—uterine cancer	4.31e-05	0.000304	CcSEcCtD
Thalidomide—Sinusitis—Doxorubicin—uterine cancer	4.29e-05	0.000302	CcSEcCtD
Thalidomide—Visual impairment—Epirubicin—uterine cancer	4.27e-05	0.000301	CcSEcCtD
Thalidomide—Agranulocytosis—Doxorubicin—uterine cancer	4.26e-05	0.0003	CcSEcCtD
Thalidomide—Erythema multiforme—Epirubicin—uterine cancer	4.19e-05	0.000295	CcSEcCtD
Thalidomide—Bradycardia—Doxorubicin—uterine cancer	4.17e-05	0.000294	CcSEcCtD
Thalidomide—Eye disorder—Epirubicin—uterine cancer	4.14e-05	0.000292	CcSEcCtD
Thalidomide—Hypersensitivity—Etoposide—uterine cancer	4.14e-05	0.000292	CcSEcCtD
Thalidomide—Tinnitus—Epirubicin—uterine cancer	4.13e-05	0.000291	CcSEcCtD
Thalidomide—Cardiac disorder—Epirubicin—uterine cancer	4.11e-05	0.00029	CcSEcCtD
Thalidomide—Rhinitis—Doxorubicin—uterine cancer	4.11e-05	0.00029	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—uterine cancer	4.1e-05	0.000289	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—uterine cancer	4.08e-05	0.000288	CcSEcCtD
Thalidomide—Pharyngitis—Doxorubicin—uterine cancer	4.07e-05	0.000287	CcSEcCtD
Thalidomide—Urinary tract disorder—Doxorubicin—uterine cancer	4.05e-05	0.000285	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—uterine cancer	4.04e-05	0.000285	CcSEcCtD
Thalidomide—Asthenia—Etoposide—uterine cancer	4.03e-05	0.000284	CcSEcCtD
Thalidomide—Angiopathy—Epirubicin—uterine cancer	4.02e-05	0.000283	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—uterine cancer	4.02e-05	0.000283	CcSEcCtD
Thalidomide—Immune system disorder—Epirubicin—uterine cancer	4e-05	0.000282	CcSEcCtD
Thalidomide—Mediastinal disorder—Epirubicin—uterine cancer	3.99e-05	0.000281	CcSEcCtD
Thalidomide—Chills—Epirubicin—uterine cancer	3.98e-05	0.00028	CcSEcCtD
Thalidomide—Pruritus—Etoposide—uterine cancer	3.97e-05	0.00028	CcSEcCtD
Thalidomide—Arrhythmia—Epirubicin—uterine cancer	3.96e-05	0.000279	CcSEcCtD
Thalidomide—Visual impairment—Doxorubicin—uterine cancer	3.95e-05	0.000278	CcSEcCtD
Thalidomide—Alopecia—Epirubicin—uterine cancer	3.92e-05	0.000276	CcSEcCtD
Thalidomide—Mental disorder—Epirubicin—uterine cancer	3.88e-05	0.000274	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—uterine cancer	3.88e-05	0.000273	CcSEcCtD
Thalidomide—Malnutrition—Epirubicin—uterine cancer	3.86e-05	0.000272	CcSEcCtD
Thalidomide—Diarrhoea—Etoposide—uterine cancer	3.84e-05	0.000271	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—uterine cancer	3.83e-05	0.00027	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—uterine cancer	3.82e-05	0.000269	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—uterine cancer	3.81e-05	0.000268	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—uterine cancer	3.8e-05	0.000268	CcSEcCtD
Thalidomide—Tension—Epirubicin—uterine cancer	3.79e-05	0.000267	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—uterine cancer	3.78e-05	0.000266	CcSEcCtD
Thalidomide—Nervousness—Epirubicin—uterine cancer	3.75e-05	0.000264	CcSEcCtD
Thalidomide—Back pain—Epirubicin—uterine cancer	3.73e-05	0.000263	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—uterine cancer	3.72e-05	0.000262	CcSEcCtD
Thalidomide—Dizziness—Etoposide—uterine cancer	3.71e-05	0.000262	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—uterine cancer	3.71e-05	0.000261	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—uterine cancer	3.7e-05	0.000261	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—uterine cancer	3.7e-05	0.00026	CcSEcCtD
Thalidomide—Chills—Doxorubicin—uterine cancer	3.68e-05	0.000259	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—uterine cancer	3.66e-05	0.000258	CcSEcCtD
Thalidomide—Vision blurred—Epirubicin—uterine cancer	3.64e-05	0.000256	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—uterine cancer	3.62e-05	0.000255	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—uterine cancer	3.59e-05	0.000253	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—uterine cancer	3.58e-05	0.000252	CcSEcCtD
Thalidomide—Vomiting—Etoposide—uterine cancer	3.57e-05	0.000252	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—uterine cancer	3.57e-05	0.000252	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—uterine cancer	3.57e-05	0.000251	CcSEcCtD
Thalidomide—Agitation—Epirubicin—uterine cancer	3.55e-05	0.00025	CcSEcCtD
Thalidomide—Rash—Etoposide—uterine cancer	3.54e-05	0.00025	CcSEcCtD
Thalidomide—Dermatitis—Etoposide—uterine cancer	3.54e-05	0.000249	CcSEcCtD
Thalidomide—Headache—Etoposide—uterine cancer	3.52e-05	0.000248	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—uterine cancer	3.52e-05	0.000248	CcSEcCtD
Thalidomide—Tension—Doxorubicin—uterine cancer	3.5e-05	0.000247	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—uterine cancer	3.5e-05	0.000246	CcSEcCtD
Thalidomide—Malaise—Epirubicin—uterine cancer	3.48e-05	0.000245	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—uterine cancer	3.47e-05	0.000244	CcSEcCtD
Thalidomide—Vertigo—Epirubicin—uterine cancer	3.47e-05	0.000244	CcSEcCtD
Thalidomide—Syncope—Epirubicin—uterine cancer	3.46e-05	0.000244	CcSEcCtD
Thalidomide—Leukopenia—Epirubicin—uterine cancer	3.45e-05	0.000243	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—uterine cancer	3.45e-05	0.000243	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—uterine cancer	3.43e-05	0.000242	CcSEcCtD
Thalidomide—Palpitations—Epirubicin—uterine cancer	3.41e-05	0.00024	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—uterine cancer	3.39e-05	0.000239	CcSEcCtD
Thalidomide—Cough—Epirubicin—uterine cancer	3.37e-05	0.000237	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—uterine cancer	3.36e-05	0.000237	CcSEcCtD
Thalidomide—Convulsion—Epirubicin—uterine cancer	3.34e-05	0.000236	CcSEcCtD
Thalidomide—Nausea—Etoposide—uterine cancer	3.34e-05	0.000235	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—uterine cancer	3.33e-05	0.000235	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—uterine cancer	3.31e-05	0.000233	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—uterine cancer	3.3e-05	0.000233	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—uterine cancer	3.28e-05	0.000231	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—uterine cancer	3.28e-05	0.000231	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—uterine cancer	3.28e-05	0.000231	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—uterine cancer	3.28e-05	0.000231	CcSEcCtD
Thalidomide—Anxiety—Epirubicin—uterine cancer	3.27e-05	0.000231	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	3.26e-05	0.00023	CcSEcCtD
Thalidomide—Discomfort—Epirubicin—uterine cancer	3.25e-05	0.000229	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—uterine cancer	3.22e-05	0.000227	CcSEcCtD
Thalidomide—Dry mouth—Epirubicin—uterine cancer	3.21e-05	0.000226	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—uterine cancer	3.21e-05	0.000226	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—uterine cancer	3.2e-05	0.000226	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—uterine cancer	3.2e-05	0.000225	CcSEcCtD
Thalidomide—Confusional state—Epirubicin—uterine cancer	3.17e-05	0.000224	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—uterine cancer	3.15e-05	0.000222	CcSEcCtD
Thalidomide—Oedema—Epirubicin—uterine cancer	3.15e-05	0.000222	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—uterine cancer	3.14e-05	0.000221	CcSEcCtD
Thalidomide—Infection—Epirubicin—uterine cancer	3.13e-05	0.00022	CcSEcCtD
Thalidomide—Cough—Doxorubicin—uterine cancer	3.11e-05	0.00022	CcSEcCtD
Thalidomide—Shock—Epirubicin—uterine cancer	3.1e-05	0.000218	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—uterine cancer	3.09e-05	0.000218	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—uterine cancer	3.09e-05	0.000218	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—uterine cancer	3.08e-05	0.000217	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—uterine cancer	3.08e-05	0.000217	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—uterine cancer	3.07e-05	0.000217	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—uterine cancer	3.06e-05	0.000216	CcSEcCtD
Thalidomide—Hyperhidrosis—Epirubicin—uterine cancer	3.04e-05	0.000215	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—uterine cancer	3.04e-05	0.000214	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—uterine cancer	3.04e-05	0.000214	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—uterine cancer	3.04e-05	0.000214	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—uterine cancer	3.03e-05	0.000213	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	3.02e-05	0.000213	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—uterine cancer	3e-05	0.000212	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—uterine cancer	3e-05	0.000212	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—uterine cancer	2.97e-05	0.000209	CcSEcCtD
Thalidomide—Hypotension—Epirubicin—uterine cancer	2.94e-05	0.000207	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—uterine cancer	2.94e-05	0.000207	CcSEcCtD
Thalidomide—Oedema—Doxorubicin—uterine cancer	2.91e-05	0.000205	CcSEcCtD
Thalidomide—Infection—Doxorubicin—uterine cancer	2.89e-05	0.000204	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Epirubicin—uterine cancer	2.87e-05	0.000202	CcSEcCtD
Thalidomide—Shock—Doxorubicin—uterine cancer	2.87e-05	0.000202	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—uterine cancer	2.86e-05	0.000201	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—uterine cancer	2.85e-05	0.000201	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—uterine cancer	2.85e-05	0.000201	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—uterine cancer	2.84e-05	0.0002	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—uterine cancer	2.83e-05	0.000199	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—uterine cancer	2.83e-05	0.000199	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—uterine cancer	2.82e-05	0.000198	CcSEcCtD
Thalidomide—Dyspnoea—Epirubicin—uterine cancer	2.81e-05	0.000198	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—uterine cancer	2.8e-05	0.000197	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—uterine cancer	2.78e-05	0.000196	CcSEcCtD
Thalidomide—Dyspepsia—Epirubicin—uterine cancer	2.77e-05	0.000195	CcSEcCtD
Thalidomide—Decreased appetite—Epirubicin—uterine cancer	2.74e-05	0.000193	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—uterine cancer	2.72e-05	0.000192	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—uterine cancer	2.72e-05	0.000192	CcSEcCtD
Thalidomide—Fatigue—Epirubicin—uterine cancer	2.71e-05	0.000191	CcSEcCtD
Thalidomide—Pain—Epirubicin—uterine cancer	2.69e-05	0.00019	CcSEcCtD
Thalidomide—Constipation—Epirubicin—uterine cancer	2.69e-05	0.00019	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—uterine cancer	2.65e-05	0.000187	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—uterine cancer	2.63e-05	0.000186	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—uterine cancer	2.62e-05	0.000184	CcSEcCtD
Thalidomide—Dyspnoea—Doxorubicin—uterine cancer	2.6e-05	0.000183	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—uterine cancer	2.59e-05	0.000183	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—uterine cancer	2.59e-05	0.000183	CcSEcCtD
Thalidomide—Gastrointestinal pain—Epirubicin—uterine cancer	2.57e-05	0.000181	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—uterine cancer	2.56e-05	0.000181	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—uterine cancer	2.53e-05	0.000178	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—uterine cancer	2.52e-05	0.000177	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—uterine cancer	2.51e-05	0.000177	CcSEcCtD
Thalidomide—Urticaria—Epirubicin—uterine cancer	2.5e-05	0.000176	CcSEcCtD
Thalidomide—Pain—Doxorubicin—uterine cancer	2.49e-05	0.000176	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—uterine cancer	2.49e-05	0.000176	CcSEcCtD
Thalidomide—Abdominal pain—Epirubicin—uterine cancer	2.49e-05	0.000175	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—uterine cancer	2.49e-05	0.000175	CcSEcCtD
Thalidomide—Feeling abnormal—Doxorubicin—uterine cancer	2.4e-05	0.000169	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—uterine cancer	2.38e-05	0.000168	CcSEcCtD
Thalidomide—Hypersensitivity—Epirubicin—uterine cancer	2.32e-05	0.000163	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—uterine cancer	2.31e-05	0.000163	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—uterine cancer	2.3e-05	0.000162	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—uterine cancer	2.3e-05	0.000162	CcSEcCtD
Thalidomide—Asthenia—Epirubicin—uterine cancer	2.26e-05	0.000159	CcSEcCtD
Thalidomide—Pruritus—Epirubicin—uterine cancer	2.23e-05	0.000157	CcSEcCtD
Thalidomide—Diarrhoea—Epirubicin—uterine cancer	2.15e-05	0.000152	CcSEcCtD
Thalidomide—Hypersensitivity—Doxorubicin—uterine cancer	2.15e-05	0.000151	CcSEcCtD
Thalidomide—Asthenia—Doxorubicin—uterine cancer	2.09e-05	0.000147	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—uterine cancer	2.08e-05	0.000147	CcSEcCtD
Thalidomide—Pruritus—Doxorubicin—uterine cancer	2.06e-05	0.000145	CcSEcCtD
Thalidomide—Vomiting—Epirubicin—uterine cancer	2e-05	0.000141	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—uterine cancer	1.99e-05	0.00014	CcSEcCtD
Thalidomide—Rash—Epirubicin—uterine cancer	1.99e-05	0.00014	CcSEcCtD
Thalidomide—Dermatitis—Epirubicin—uterine cancer	1.98e-05	0.00014	CcSEcCtD
Thalidomide—Headache—Epirubicin—uterine cancer	1.97e-05	0.000139	CcSEcCtD
Thalidomide—Dizziness—Doxorubicin—uterine cancer	1.93e-05	0.000136	CcSEcCtD
Thalidomide—Nausea—Epirubicin—uterine cancer	1.87e-05	0.000132	CcSEcCtD
Thalidomide—Vomiting—Doxorubicin—uterine cancer	1.85e-05	0.000131	CcSEcCtD
Thalidomide—Rash—Doxorubicin—uterine cancer	1.84e-05	0.000129	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—uterine cancer	1.84e-05	0.000129	CcSEcCtD
Thalidomide—Headache—Doxorubicin—uterine cancer	1.83e-05	0.000129	CcSEcCtD
Thalidomide—Nausea—Doxorubicin—uterine cancer	1.73e-05	0.000122	CcSEcCtD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.29e-05	0.000164	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.29e-05	0.000164	CbGpPWpGaD
Thalidomide—PTGS2—Disease—DCN—uterine cancer	1.29e-05	0.000163	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KRAS—uterine cancer	1.28e-05	0.000162	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP11A1—uterine cancer	1.28e-05	0.000162	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—uterine cancer	1.26e-05	0.00016	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STK11—uterine cancer	1.26e-05	0.00016	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POLD1—uterine cancer	1.25e-05	0.000159	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POLD1—uterine cancer	1.25e-05	0.000159	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—uterine cancer	1.25e-05	0.000158	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKR1C1—uterine cancer	1.25e-05	0.000158	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SOCS3—uterine cancer	1.24e-05	0.000157	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKR1B1—uterine cancer	1.23e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—STAR—uterine cancer	1.23e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.22e-05	0.000155	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.22e-05	0.000155	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EP300—uterine cancer	1.21e-05	0.000154	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKR1C3—uterine cancer	1.21e-05	0.000153	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—uterine cancer	1.2e-05	0.000152	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDH1—uterine cancer	1.19e-05	0.000151	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN2B—uterine cancer	1.19e-05	0.000151	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.19e-05	0.00015	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POLD1—uterine cancer	1.18e-05	0.00015	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SOCS3—uterine cancer	1.18e-05	0.000149	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKR1C1—uterine cancer	1.17e-05	0.000149	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKR1C1—uterine cancer	1.17e-05	0.000148	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1R—uterine cancer	1.15e-05	0.000146	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—uterine cancer	1.15e-05	0.000145	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.15e-05	0.000145	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKR1C3—uterine cancer	1.15e-05	0.000145	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NRAS—uterine cancer	1.13e-05	0.000144	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDH1—uterine cancer	1.13e-05	0.000143	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KRAS—uterine cancer	1.13e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN2B—uterine cancer	1.13e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—STAR—uterine cancer	1.12e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.12e-05	0.000143	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HMGA1—uterine cancer	1.12e-05	0.000142	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.11e-05	0.000141	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—RRM2—uterine cancer	1.11e-05	0.000141	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKR1C1—uterine cancer	1.11e-05	0.00014	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1R—uterine cancer	1.1e-05	0.000139	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—uterine cancer	1.09e-05	0.000138	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KRAS—uterine cancer	1.09e-05	0.000138	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SMAD3—uterine cancer	1.09e-05	0.000138	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—DCN—uterine cancer	1.08e-05	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KRAS—uterine cancer	1.07e-05	0.000136	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—RRM2—uterine cancer	1.05e-05	0.000133	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—RRM2—uterine cancer	1.04e-05	0.000132	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PIK3CA—uterine cancer	1.04e-05	0.000132	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGFR2—uterine cancer	1.04e-05	0.000131	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KRAS—uterine cancer	1.03e-05	0.000131	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SMAD3—uterine cancer	1.03e-05	0.000131	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FBXW7—uterine cancer	1.02e-05	0.000129	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP11A1—uterine cancer	1.02e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—DCN—uterine cancer	1.02e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—DCN—uterine cancer	1.01e-05	0.000128	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB2—uterine cancer	1.01e-05	0.000128	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PIK3CA—uterine cancer	9.98e-06	0.000126	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—RRM2—uterine cancer	9.86e-06	0.000125	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PIK3CA—uterine cancer	9.86e-06	0.000125	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KRAS—uterine cancer	9.76e-06	0.000124	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	9.69e-06	0.000123	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POLD1—uterine cancer	9.68e-06	0.000123	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—uterine cancer	9.61e-06	0.000122	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—AKT1—uterine cancer	9.61e-06	0.000122	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—STAR—uterine cancer	9.61e-06	0.000122	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKR1B1—uterine cancer	9.61e-06	0.000122	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKR1C3—uterine cancer	9.6e-06	0.000122	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—DCN—uterine cancer	9.57e-06	0.000121	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP11A1—uterine cancer	9.57e-06	0.000121	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP11A1—uterine cancer	9.55e-06	0.000121	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB2—uterine cancer	9.54e-06	0.000121	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	9.5e-06	0.00012	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PIK3CA—uterine cancer	9.47e-06	0.00012	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—STK11—uterine cancer	9.42e-06	0.000119	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP19A1—uterine cancer	9.42e-06	0.000119	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDKN1B—uterine cancer	9.32e-06	0.000118	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—uterine cancer	9.23e-06	0.000117	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—uterine cancer	9.12e-06	0.000116	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKR1C1—uterine cancer	9.05e-06	0.000115	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKR1C3—uterine cancer	9.03e-06	0.000115	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP11A1—uterine cancer	9.02e-06	0.000114	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKR1C3—uterine cancer	9.01e-06	0.000114	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ESR1—uterine cancer	8.86e-06	0.000112	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.84e-06	0.000112	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDKN1B—uterine cancer	8.84e-06	0.000112	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POLD1—uterine cancer	8.83e-06	0.000112	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB2—uterine cancer	8.81e-06	0.000112	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTNNB1—uterine cancer	8.8e-06	0.000112	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—uterine cancer	8.76e-06	0.000111	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTEN—uterine cancer	8.58e-06	0.000109	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKR1C3—uterine cancer	8.52e-06	0.000108	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—uterine cancer	8.49e-06	0.000108	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	8.43e-06	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ESR1—uterine cancer	8.41e-06	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTNNB1—uterine cancer	8.35e-06	0.000106	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—uterine cancer	8.29e-06	0.000105	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKR1C1—uterine cancer	8.25e-06	0.000105	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EP300—uterine cancer	8.18e-06	0.000104	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN1B—uterine cancer	8.16e-06	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—uterine cancer	8.15e-06	0.000103	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTEN—uterine cancer	8.14e-06	0.000103	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—RRM2—uterine cancer	8.07e-06	0.000102	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—uterine cancer	8.05e-06	0.000102	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN2B—uterine cancer	8e-06	0.000101	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DCN—uterine cancer	7.83e-06	9.93e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—uterine cancer	7.8e-06	9.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EP300—uterine cancer	7.76e-06	9.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—uterine cancer	7.73e-06	9.8e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CTNNB1—uterine cancer	7.71e-06	9.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—uterine cancer	7.65e-06	9.7e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POLD1—uterine cancer	7.54e-06	9.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTEN—uterine cancer	7.51e-06	9.53e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—STK11—uterine cancer	7.48e-06	9.48e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP19A1—uterine cancer	7.48e-06	9.48e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—uterine cancer	7.4e-06	9.38e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP11A1—uterine cancer	7.38e-06	9.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—RRM2—uterine cancer	7.36e-06	9.33e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—uterine cancer	7.32e-06	9.28e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SMAD3—uterine cancer	7.31e-06	9.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—uterine cancer	7.26e-06	9.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EP300—uterine cancer	7.17e-06	9.08e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DCN—uterine cancer	7.14e-06	9.05e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—uterine cancer	7.08e-06	8.97e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKR1C1—uterine cancer	7.05e-06	8.94e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—STK11—uterine cancer	7.04e-06	8.92e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP19A1—uterine cancer	7.04e-06	8.92e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—STK11—uterine cancer	7.02e-06	8.9e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP19A1—uterine cancer	7.02e-06	8.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.02e-06	8.9e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKR1C3—uterine cancer	6.97e-06	8.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR2—uterine cancer	6.97e-06	8.83e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP11A1—uterine cancer	6.73e-06	8.53e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—uterine cancer	6.71e-06	8.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—uterine cancer	6.7e-06	8.5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.69e-06	8.48e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—STK11—uterine cancer	6.64e-06	8.41e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP19A1—uterine cancer	6.64e-06	8.41e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—uterine cancer	6.59e-06	8.35e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—uterine cancer	6.5e-06	8.24e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKR1C3—uterine cancer	6.35e-06	8.06e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RRM2—uterine cancer	6.29e-06	7.97e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—uterine cancer	6.25e-06	7.92e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.24e-06	7.91e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.23e-06	7.9e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—uterine cancer	6.17e-06	7.82e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—uterine cancer	6.17e-06	7.82e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DCN—uterine cancer	6.1e-06	7.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—uterine cancer	6.05e-06	7.67e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1B—uterine cancer	6.02e-06	7.64e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.94e-06	7.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—uterine cancer	5.85e-06	7.42e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—uterine cancer	5.77e-06	7.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP11A1—uterine cancer	5.75e-06	7.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—uterine cancer	5.74e-06	7.28e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1B—uterine cancer	5.72e-06	7.24e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—uterine cancer	5.69e-06	7.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—uterine cancer	5.62e-06	7.12e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—uterine cancer	5.6e-06	7.1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—uterine cancer	5.55e-06	7.03e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKR1C3—uterine cancer	5.43e-06	6.88e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP19A1—uterine cancer	5.43e-06	6.88e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—STK11—uterine cancer	5.43e-06	6.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—uterine cancer	5.4e-06	6.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—uterine cancer	5.31e-06	6.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—uterine cancer	5.3e-06	6.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—uterine cancer	5.29e-06	6.7e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—uterine cancer	5.29e-06	6.7e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—uterine cancer	5.28e-06	6.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—uterine cancer	5.26e-06	6.67e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.1e-06	6.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—uterine cancer	5.02e-06	6.36e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—uterine cancer	5.01e-06	6.35e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—uterine cancer	4.99e-06	6.32e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—STK11—uterine cancer	4.95e-06	6.28e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP19A1—uterine cancer	4.95e-06	6.28e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.95e-06	6.28e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—uterine cancer	4.95e-06	6.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—uterine cancer	4.94e-06	6.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—uterine cancer	4.9e-06	6.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.86e-06	6.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—uterine cancer	4.75e-06	6.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—uterine cancer	4.69e-06	5.95e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—uterine cancer	4.69e-06	5.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.65e-06	5.89e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.43e-06	5.62e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.39e-06	5.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—uterine cancer	4.38e-06	5.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—uterine cancer	4.33e-06	5.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—uterine cancer	4.26e-06	5.4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—STK11—uterine cancer	4.23e-06	5.36e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP19A1—uterine cancer	4.23e-06	5.36e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—uterine cancer	4.08e-06	5.17e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1B—uterine cancer	4.05e-06	5.14e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—uterine cancer	4.04e-06	5.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.97e-06	5.03e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—uterine cancer	3.94e-06	4.99e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—uterine cancer	3.91e-06	4.96e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—uterine cancer	3.83e-06	4.85e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.79e-06	4.8e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—uterine cancer	3.79e-06	4.8e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—uterine cancer	3.75e-06	4.76e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—uterine cancer	3.73e-06	4.73e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—uterine cancer	3.72e-06	4.72e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—uterine cancer	3.71e-06	4.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—uterine cancer	3.62e-06	4.59e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.6e-06	4.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—uterine cancer	3.59e-06	4.55e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—uterine cancer	3.56e-06	4.51e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—uterine cancer	3.43e-06	4.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—uterine cancer	3.33e-06	4.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.28e-06	4.16e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—uterine cancer	3.2e-06	4.05e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—uterine cancer	3.18e-06	4.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—uterine cancer	3.13e-06	3.96e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—uterine cancer	3.03e-06	3.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—uterine cancer	2.98e-06	3.78e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—uterine cancer	2.94e-06	3.73e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—uterine cancer	2.94e-06	3.72e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—uterine cancer	2.87e-06	3.63e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—uterine cancer	2.81e-06	3.56e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.8e-06	3.55e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—uterine cancer	2.8e-06	3.55e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—uterine cancer	2.78e-06	3.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—uterine cancer	2.77e-06	3.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—uterine cancer	2.65e-06	3.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—uterine cancer	2.63e-06	3.34e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—uterine cancer	2.44e-06	3.09e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—uterine cancer	2.27e-06	2.88e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—uterine cancer	2.27e-06	2.88e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—uterine cancer	2.2e-06	2.8e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—uterine cancer	2.16e-06	2.74e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—uterine cancer	2.15e-06	2.73e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—uterine cancer	2.08e-06	2.63e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.07e-06	2.63e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—uterine cancer	2.07e-06	2.62e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—uterine cancer	1.97e-06	2.5e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—uterine cancer	1.96e-06	2.48e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—uterine cancer	1.8e-06	2.28e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—uterine cancer	1.77e-06	2.24e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—uterine cancer	1.7e-06	2.15e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—uterine cancer	1.69e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—uterine cancer	1.69e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.6e-06	2.03e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—uterine cancer	1.6e-06	2.03e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.46e-06	1.85e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—uterine cancer	1.31e-06	1.66e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.25e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—uterine cancer	1.19e-06	1.51e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—uterine cancer	1.02e-06	1.29e-05	CbGpPWpGaD
